rtc110, I say sell to BP and then let them choose their preferred
strategy. BP will make the decisions that suit them. If the supply
of Vascepa turns out to be in short supply in a few years, BP could
make the product available to wherever the price is the best. BP
would have stronger resources to fight generics...political, economic,
legal, and financial. If generics do make it to market at some point
they could place that supply in Europe or other parts of the world.
Also, on any appeal, maybe a judge would be less likely to cross a
politically connected BP than it would an unknown little Irish company.
News 
Market Data 
Discover 
